The Department of Veterans Affairs announced on Aug. 24 that it has secured more than $10 billion in pharmaceutical price reductions so far in fiscal year 2026, savings the department said enable it to treat more veterans with the same or lower expenditure.
The VA uses a combination of Federal Supply Schedule pricing and pharmaceutical benefit management negotiations to achieve pricing advantages over market rates. The $10 billion figure represents savings versus published market prices, not cash savings from an existing budget baseline, according to the department.
The VA’s pharmaceutical purchasing power is among the strongest in the federal government. By law, the VA receives mandated discounts on prescription drugs through the Federal Supply Schedule and can negotiate further reductions through its national formulary process.
The savings free resources for expanded services across the VA health system, which serves approximately nine million enrolled veterans annually. Drug costs represent one of the largest and fastest-growing components of the VA’s health care budget.
The announcement comes as the administration emphasizes the VA’s purchasing model as a potential template for broader federal drug pricing reform. The VA consistently pays lower prices for prescription drugs than Medicare, Medicaid and most private insurers.
Congressional advocates for Medicare drug price negotiation have pointed to the VA’s experience as evidence that direct government negotiation produces meaningful cost reductions without reducing access to medications.
The pharmaceutical industry has historically argued that the VA’s pricing model cannot be scaled to the broader market without reducing manufacturer incentives for research and development. The Pharmaceutical Research and Manufacturers of America has cautioned against policies that extend VA-style pricing to Medicare or other federal programs.